Skip to main content

Table 3 Summary details

From: Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy

Reason treatment ended:  
Progressive disease N=12, 100%
Best response:  
Stable disease N=4, 33.33%
Progressive disease N=8, 66.67%
Number of treatment weeks completed  
N 12
Mean 7.9
Std 4.72
Min 4
Max 20
Duration of stable disease (weeks)  
N 4
Mean 13.03
Std 3.28
Min 10.9
Max 17.9
Progression-free survival: median of 5.7 weeks.  
Survival status  
Alive N=1, 8.33%
Dead N=11, 91.67%